Cystic fibrosis: questions on the new drug Vertex

Published: 23 July 2014
WhatInvestors and patients were exuberant when Vertex Pharmaceuticals released results from clinical trials showing that cystic fibrosis (CF) patients’ lung function improved on an experimental two-drug regimen. But  two independent teams of scientists, one from McGill University, published studies showing that the medications interfere with each other, at least when they are administered to human cells in a laboratory dish.


The studies published in the journal Science Translational Medicine raise fundamental questions about how the drugs work in CF patients and also suggest that a different strategy might be more effective.


Expertise: McGill prof. Gergely Lukacs, Faculty of Medicine (Physiology), Canada Research Chair in Cystic Fibrosis

Link to research  

Source: The Boston Globe

Back to top